Search

Krzysztof J Grzegorzewski

from Randolph, NJ
Age ~66
Get Report
Also known as:
Kris J Grzegorzewski, Kris Dr Grzegorzewski, Krzysztof P Grzegorzewski, Krzysztof Grzegorzewski Dr, Katrina J Grzegorzewski, Kris Gregorsky, Kj Grzegorzewski, Krzyztof Grezegorzewski
Phone and address:
35 Everdale Rd, Dover, NJ 07869
(240) 401-5476
Related to:
Thomas P Delehanty, 85Kenneth Whitehead, 55Kenneth L Whitehead, 82Nicholas Thompson, 46Tammy L Lynch, 51
Connected to:
Artur J Grzegorczyk, 55Dennis A Grzegorczyk, 71Katarzyna A Grzegorczyk, 44Keith J Grzegorek, 45Lauren C Grzegorczyk, 26Marta J Grzegorczyk, 46Monika W Grzegorczyk, 43Stephen M Grzegorzewski, 70Harold W Grzejka, 77Michael Grzejka, 31

Krzysztof Grzegorzewski Phones & Addresses

  • 35 Everdale Rd, Randolph, NJ 07869 (240) 401-5476
  • 57 Quail Dr S, Phoenixville, PA 19460
  • 14403 Rimfire Ct, Boyds, MD 20841
  • 20040 Hob Hill Way, Montgomery Village, MD 20886
  • Gaithersburg, MD
  • Frazer, PA
  • Morgan, NJ
  • Montgomery, PA

Work

Position: Precision Production Occupations

Education

Degree: High school graduate or higher

Public records

Vehicle Records

Krzysztof Grzegorzewski

View page
Address:
35 Everdale Rd, Randolph, NJ 07869
VIN:
WBANF73567CU24809
Make:
BMW
Model:
5 SERIES
Year:
2007

Resumes

Resumes

Krzysztof Grzegorzewski Photo 1

Krzysztof Grzegorzewski

View page

Publications

Us Patents

Methods Of Treating Or Preventing Cell, Tissue, And Organ Damage Using Human Myeloid Progenitor Inhibitory Factor-1 (Mpif-1)

View page
US Patent:
20030114379, Jun 19, 2003
Filed:
Oct 2, 2002
Appl. No.:
10/261950
Inventors:
Haodong Li - Gaithersburg MD, US
Steven Ruben - Olney MD, US
Krzysztof Grzegorzewski - Gaithersburg MD, US
Craig Rosen - Laytonsville MD, US
Vikram Patel - Germantown MD, US
Reinder Gentz - Rockville MD, US
Assignee:
Human Genome Sciences, Inc.
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
There are disclosed therapeutic compositions and methods using isolated nucleic acid molecules encoding a human myeloid progenitor inhibitory factor-1 (MPIF-1) polypeptide (previously termed MIP-3 and chemokine 8 (CK8 or ckb-8)), as well as MPIF-1 polypeptide itself, as are vectors, host cells and recombinant methods for producing the same.

Method Of Mobilizing Pluripotential Hematopoietic Stem Cells With Il-7

View page
US Patent:
56373236, Jun 10, 1997
Filed:
Nov 16, 1994
Appl. No.:
8/341399
Inventors:
Robert H. Wiltrout - Frederick MD
Francis Ruscetti - New Market MD
Krzysztof Grzegorzewski - Montgomery Village MD
Jonathan Keller - Frederick MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12N 1585
A61K 3514
A01N 6300
US Classification:
424534
Abstract:
This invention provides a method of isolating an increased number of hematopoietic stem cells from a subject comprising a) administering interleukin-7 to the subject in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; and, b) isolating a population of leukocytes enriched for hematopoietic stem cells from the peripheral blood. Also provided is a method of transplanting an increased number of hematopoietic stem cells from a donor to a recipient to enhance repopulation of the recipient's hematopoietic and immune cells comprising a) administering interleukin-7 to the donor in an amount that mobilizes the hematopoietic stem cells to the peripheral blood; b) isolating a population of leukocytes enriched for hematopoietic stem cells from the donor's peripheral blood; and, c) transplanting the isolated population of leukocytes enriched for hematopoietic stem cells to the recipient, thereby enhancing the repopulation of the recipient's hematopoietic and immune cells. Finally, the invention provides a method of improving engraftment of a bone marrow transplant or a peripheral blood leukocyte transplant from a donor to a recipient comprising administering interleukin-7 to the recipient following transplantation in an amount that enhances engraftment.

Specific Anti-Cd38 Antibodies For Treating Human Cancers

View page
US Patent:
20190284294, Sep 19, 2019
Filed:
Nov 21, 2018
Appl. No.:
16/198209
Inventors:
- Paris, FR
Krzysztof J. GRZEGORZEWSKI - Randolph NJ, US
Marie-Laure OZOUX - Paris, FR
Blake TOMKINSON - Weston MA, US
International Classification:
C07K 16/28
A61K 31/573
Abstract:
The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38 cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

Specific Anti-Cd38 Antibodies For Treating Human Cancers

View page
US Patent:
20180022814, Jan 25, 2018
Filed:
Apr 5, 2017
Appl. No.:
15/479500
Inventors:
- Paris, FR
Krzysztof J. Grzegorzewski - Randolph NJ, US
Marie-Laure Ozoux - Paris, FR
Blake Tomkinson - Weston MA, US
International Classification:
C07K 16/28
A61K 31/573
A61K 39/395
A61K 39/00
Abstract:
The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38 cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

Specific Anti-Cd38 Antibodies For Treating Human Cancers

View page
US Patent:
20150118251, Apr 30, 2015
Filed:
Oct 31, 2014
Appl. No.:
14/529719
Inventors:
- Paris, FR
Krzysztof J. Grzegorzewski - Randolph NJ, US
Marie-Laure Ozoux - Paris, FR
Blake Tomkinson - Weston MA, US
International Classification:
C07K 16/28
A61K 39/395
A61K 31/573
US Classification:
4241721
Abstract:
The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38 cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.
Control profile
Krzysztof J Grzegorzewski from Randolph, NJ, age ~66 Get Report